UNASSIGNED: Introduction: Electroconvulsive treatment (ECT) is an effective treatment for severe @entity308 but carries a risk of relapse in the following months. Methods: Major @entity308 @entity1 in a current episode attaining remission from ECT (17-item Hamilton Depression Rating Scale (HAM-D17) score <=9) received randomly @entity837 10   mg, 20   mg, 30   mg or @entity5080 100   mg as monotherapies and were followed for 6 months in a multicentre double-blind set-up. Primary endpoint was relapse (HAM-D17>= 16). Results: As inclusion rate was low the study was prematurely stopped with only 47 @entity1 randomised (20% of the planned sample size). No statistically significant between-group differences could be detected. When all @entity1 receiving @entity837 were compared with those receiving @entity5080 , a marginal superiority of @entity5080 was found (p=0.08). One third of @entity1 relapsed during the study period, and one third completed. Discussion: Due to small sample size, no valid efficacy inferences could be made. The outcome was poor, probably due to tapering off of non-study psychotropic drugs after randomisation; this has implications for future study designs. ClinicalTrials.gov Identifier: NCT00660062.

Relapse Prevention in Major XXXX After Successful Acute Electroconvulsive Treatment: a 6-month Double-blind Comparison of Three Fixed Dosages of @entity837 and a Fixed Dose of @entity5080 - Lessons from a Failed Randomised Trial of the Danish University Antidepressant Group (DUAG-7).

@entity1 :: ('9606', 'Species') :: ['patients'] @entity837 :: ('MESH:D015283', 'Chemical') :: ['escitalopram'] @entity5080 :: ('MESH:D009661', 'Chemical') :: ['nortriptyline'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive disorder', 'depression']
@entity308 :: (MESH:D003866,Disease) :: ['Depressive Disorder']
